US FDA Eyes New Investigational Drug Label Requirements That Bring International Harmonization
To help reduce medication errors that can harm patients and compromise research results, FDA – pushed by clinical trial sites – looks to exert more control of the labels of investigational drug products.
You may also be interested in...
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.
Final guidance excludes stool banks, putting in place more limited enforcement discretion regarding the requirement of an investigational new drug application for use of fecal transplants to treat C. diff infections, likely paving way for shift to any FDA-approved product.
Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.